News for Precigen, Inc. (PGEN)

Longtime drug developer Suma Krishnan was 51 when she cofounded Krystal Biotech. Now the company has one gene therapy on the market and more in the works.

The FDA decision on PharmaTher Holdings' resubmitted Abbreviated New Drug Application for racemic ketamine KETARX is due on August 9, 2025..

U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session af...

Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026. Click here to find out why PGEN is a Buy.

U.S. stocks were mixed, with the Dow Jones index falling over 100 points on Wednesday. Shares of Hut 8 Corp. HUT rose sharply during Wednesday's session after ...

On May 15, 2025, Cantor Fitzgerald's analyst, Jennifer Kim, reiterated her rating for Precigen (PGEN) as

\n Precigen (PGEN) and the Recurrent Respiratory Papillomatosis Foundation (RRPF) will co-host the 2025 International RRP Awareness Day on June 11 in Washingt

Precigen Inc (PGEN) is set to release its Q4 2024 earnings on Mar 19, 2025. The consensus estimate for Q4 2024 revenue is $0.73 million, and the earnings are ex

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Friday. Shares of Scholastic Corporation SCHL rose sharply during Friday's sessio...

Net Loss: $126.2 million for 2024, compared to $95.9 million in 2023.Net Loss Per Share: $0.47 per basic and diluted share for 2024, compared to $0.39 in 2023.

Mar 19, 2025 / 08:30PM GMTOperator Good evening and welcome to the Precigen's Full Year 2024 Financial Results and Business Update Call. (Operator Instructions)

Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ETCompany ParticipantsSteven Harasym - IRHelen Sabzevari - President...

Precigen (PGEN) delivered earnings and revenue surprises of 33.33% and 2.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireGERMANTOWN, Md., March 19, 2025 FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respirator

Revenue: Total revenues decreased by $2.3 million, or 37%, compared to the previous year, primarily due to reductions in product and service volumes at Exempla

PR NewswireGERMANTOWN, Md., March 13, 2025 GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company speci

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Precigen, Inc.

Discover groundbreaking advancements in RRP treatment as FDA reviews PRGN-2012.

PR NewswireGERMANTOWN, Md., Feb. 25, 2025 ”“ Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, wo